Event: Pharma China Seminar 2013 - Building Success in China’s Pharma Sector
Sponsors: Boston Healthcare Associates and Others TBA
Date(s): April 16, 2013
Venue: Marriott at Forrestal, Princeton, New Jersey, USA
Brochure: PharmaChinaSeminar-2013.pdf
Contact: Kelly Yueh
Tel: +1 212-2287974 or +1 713-3986888
Email: info@pharmachinaseminar.com or kelly@pharmachinaseminar.com
Website: www.pharmachinaseminar.com

The Chinese pharmaceutical industry and market in 2012 was characterized by slowing growth, falling profitability, mixed regulatory developments setting higher industry standards to improve drug safety and boosting drug review efficiency, renewed price cutting initiatives disregarding higher costs and expenditures of the industry, superficial healthcare reform progress driven primarily by cost containment measures, fallen healthcare quality & growing drug safety incidents, worsening patient-physician relations, and non-stop repositioning of the pharma industry adapting to new realities.

As predicted, China’s ongoing healthcare reform last year was limited by structural flaws, lack of central government will to finance reform, failures to coordinate agendas of different agencies and balance conflicting interest of stakeholders, fiscal challenges of local governments, and belated reform of the medical service industry.

The Chinese government at the central and local levels did step up their healthcare investment somewhat, but it is far from enough to finance the reform goals, the healthcare reform last year continued to be driven primarily by comprehensive cost cutting initiatives.

Besides, Central government agencies including SFDA, MOH and NDRC have been leading the efforts of strengthening drug regulation with emphasis on price control, drug safety, GMP implementation, drug registration system reform and OTC drug management, while other agencies such as MOFCOM and the MIIT have stepped up their industrial management role of the pharmaceutical industry.

Faced with unprecedented challenges, large pharmaceutical companies, represented by state-controlled companies and MNCs, continued to reposition themselves through M&As, diversification drives, alliances and partnerships, and capacity building for both manufacturing and R&D.

In fact, the pharmaceutical industry in China continued to outperform other industries last year in spite of a fresh array of policy turbulences, slowing economy and a host of other challenges, and it managed to grow at around 20%.

MOH stated recently that the healthcare reform has reached a stage of "deep water" and "tough battle" and the government must emphasize its efforts on major issues including primary healthcare, basic medical insurance and essential drugs in 2013.

There is no doubt the healthcare reform will go on with unchanged slogans. In reality, both central and local governments will be more financially strapped this year to achieve original reform objectives and they will be forced to rely on cost containment even more. The aftermath will be fallen quality of healthcare, increased safety incidents and reduced overall healthcare efficiency, potentially leading to social unrests in a period of political sensitivity.

Given the present market environment, it is generally anticipated that pharmaceutical industry and market growth in the near future would no longer match the high rates seen in 2010 and 2011.

But don’t be discouraged prematurely. The upcoming Year of Snake in 2013 is also meant for steady progress and achievement for those with creativity, focus and discipline. Only those with flexibility and creative strategies will succeed in this increasingly complex and challenging market.

Despite growing challenges on the ground in China, there are success stories from all categories of players, whether they are foreign or local, large or small, newcomer or established, private or state-owned. However, to be one of the success stories require a thorough understanding of the sector, ability to face and tackle challenges, flexibility to deal with changes, and skills to maneuver through complex situations.

To cater for the growing needs of headquarter pharmaceutical executives for better understanding of the Chinese market, the Seminar was launched in 2009 by Pharma China, the most trusted English media and source of business intelligence covering the Chinese pharmaceutical / biopharmaceutical industry and market, and AmIntell, the organizer of Pharma CI Conference and Pharma Market Research Conference.

"Pharma China Seminar - Building Success in China’s Pharma Sector" is a one-day seminar providing insights into contemporary trends/issues and the most important aspects of the Chinese pharmaceutical industry and marketplace today.

On the basis of our successful experience with the event in the past four years, Pharma China Seminar 2013 will refocus its agenda to provide more in-depth coverage of and strategic insights into four key aspects of Chinese pharma business including 1) latest trends and issues in drug regulation and healthcare policies, 2) impacts of deepening healthcare reform on the pharma industry; 3) changing dynamics in pharma marketing & distribution channels, 4) changing role of China in global supply chain of pharma companies; 5) R&D, partnership and licensing trends & strategies; 6) dynamic healthcare and disease trends, 7) creative business and marketing strategies and solutions, 8) emerging IP/legal issues, and 9) new opportunity areas such as biosimilars.

At least ten leading experts of the Chinese pharmaceutical/healthcare sector with different specialization will share their expertise and knowledge through exclusive data, detailed analysis, case studies and interactive panel discussions.

Who should attend?

For registration and information, please contact: Kelly Yueh
Tel: +1 212 228 7974 or +1 713 398 6888
Email: kelly@pharmachinaseminar.com or info@pharmachinaseminar.com